- Home
- ZBIO vs ELDN Comparison
ZBIO vs ELDN Comparison
Compare ZBIO & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- ELDN
- Stock Information
- Founded
- ZBIO 2019
- ELDN 2004
- Country
- ZBIO United States
- ELDN United States
- Employees
- ZBIO N/A
- ELDN N/A
- Industry
- ZBIO
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- ZBIO
- ELDN Health Care
- Exchange
- ZBIO NYSE
- ELDN Nasdaq
- Market Cap
- ZBIO 268.7M
- ELDN 288.5M
- IPO Year
- ZBIO 2024
- ELDN N/A
- Fundamental
- Price
- ZBIO $7.83
- ELDN $4.29
- Analyst Decision
- ZBIO Strong Buy
- ELDN Strong Buy
- Analyst Count
- ZBIO 6
- ELDN 1
- Target Price
- ZBIO $29.20
- ELDN $16.00
- AVG Volume (30 Days)
- ZBIO 207.0K
- ELDN 232.7K
- Earning Date
- ZBIO 03-04-2025
- ELDN 03-27-2025
- Dividend Yield
- ZBIO N/A
- ELDN N/A
- EPS Growth
- ZBIO N/A
- ELDN N/A
- EPS
- ZBIO N/A
- ELDN N/A
- Revenue
- ZBIO N/A
- ELDN N/A
- Revenue This Year
- ZBIO N/A
- ELDN N/A
- Revenue Next Year
- ZBIO N/A
- ELDN N/A
- P/E Ratio
- ZBIO N/A
- ELDN N/A
- Revenue Growth
- ZBIO N/A
- ELDN N/A
- 52 Week Low
- ZBIO $5.83
- ELDN $1.52
- 52 Week High
- ZBIO $26.25
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- ELDN 44.28
- Support Level
- ZBIO N/A
- ELDN $4.40
- Resistance Level
- ZBIO N/A
- ELDN $4.65
- Average True Range (ATR)
- ZBIO 0.00
- ELDN 0.23
- MACD
- ZBIO 0.00
- ELDN -0.04
- Stochastic Oscillator
- ZBIO 0.00
- ELDN 8.16
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.